Blood transfusions in septic shock: is 7.0g/dL really the appropriate threshold?

ABSTRACT

Objective: To evaluate the immediate effects of red blood cell transfusion on central venous oxygen saturation and lactate levels in septic shock patients with different transfusion triggers.

Methods: We included patients with a diagnosis of septic shock within the last 48 hours and hemoglobin levels below 9.0g/dL. Patients were randomized for immediate transfusion with hemoglobin concentrations maintained above 9.0g/dL (Group Hb9) or to withhold transfusion unless hemoglobin fell below 7.0g/dL (Group Hb7). Hemoglobin, lactate, central venous oxygen saturation levels were determined before and one hour after each transfusion.

Results: We included 46 patients and 74 transfusions. Patients in Group Hb7 had a significant reduction in median lactate from 2.44 (2.00 - 3.22) mMol/L to 2.21 (1.80 - 2.79) mMol/L, p = 0.005, which was not observed in Group Hb9 [1.90 (1.80 - 2.65) mMol/L to 2.00 (1.70 - 2.41) mMol/L, p = 0.23]. Central venous oxygen saturation levels increased in Group Hb7 [68.0 (64.0 - 72.0)% to 72.0 (69.0 - 75.0)%], p < 0.0001] but not in Group Hb9 [72.0 (69.0 - 74.0)% to 72.0 (71.0 - 73.0)%], p = 0.98. Patients with elevated lactate or central venous oxygen saturation < 70% at baseline had a significant increase in these variables, regardless of baseline hemoglobin levels. Patients with normal values did not show a decrease in either group.

Conclusion: Red blood cell transfusion increased central venous oxygen saturation and decreased lactate levels in patients with hypoperfusion regardless of their baseline hemoglobin levels. Transfusion did not appear to impair these variables in patients without hypoperfusion.

ClinicalTrials.gov NCT01611753

Keywords: Erythrocyte transfusion; Ischemia; Shock, septic; Sepsis; Oxygenation

INTRODUCTION

Sepsis is a common condition associated with both high costs and mortality and is usually related to multiple organ dysfunction. One of the primary mechanisms for organ dysfunction is inadequate cellular metabolism due to alterations in oxygen supply and consumption. Adequate hemoglobin (Hb) levels could theoretically increase arterial oxygen content and thus improve tissue oxygen delivery. However, there are no conclusive data regarding the optimal level of Hb in septic shock patients.
Although it is not clear that alterations in the central venous oxygen saturation (ScvO₂) and lactate levels actually represent improvements in the oxygen delivery/oxygen consumption ratio these alterations may be a better indication for transfusion than the absolute Hb value. Studies on the effects of transfusion on oxygen transport variables have yielded conflicting results, with some trials showing an increase in oxygen delivery/oxygen consumption ratio while others show no increase.\textsuperscript{(12-17)} Some authors have recently suggested that these variables could help to identify surgical patients who would benefit from transfusion.\textsuperscript{(18)} Others have shown that muscle tissue oxygenation, oxygen consumption and microvascular reactivity as assessed by near-infrared spectroscopy improve after transfusion only in patients with alterations in these variables at baseline.\textsuperscript{(19)}

Rivers et al. demonstrated a significant reduction in hospital mortality rates among patients who were randomized to undergo early goal-directed therapy that included red blood cell (RBC) transfusion.\textsuperscript{(20)} However, a clear relationship between blood transfusion and improved outcomes could not be demonstrated with this type of study. Recently, Holst et al. randomized 998 septic shock patients to a restrictive or liberal transfusion strategy;\textsuperscript{(21)} they could not find any difference between those patients assigned to be transfused only if Hb levels were below 7.0 and those with Hb 9.0g/dL as a trigger. However, those patients were transfused throughout their intensive care unit (ICU) stay, regardless of their tissue oxygenation variables, which reduces the relevance of the study’s findings. The primary controversy concerns the potential benefits of transfusion in patients with signs of hypoperfusion and Hb levels over 7.0g/dL.

Therefore, we designed a physiological study to determine the effects of RBC transfusion on ScvO₂ and lactate levels in septic shock patients who were randomized into two groups with different Hb levels. Although increased Hb levels will hypothetically increase oxygen content and oxygen delivery on a mathematical basis, we hypothesized that this would increase ScvO₂ only if Hb levels were below 7.0g/dL. It is possible that with higher Hb levels, this contribution differs from lower levels, which supports a restrictive approach to transfusion. The goal of this study was to test this hypothesis in random populations of patients in whom transfusion was indicated as Hb fell below 9.0g/dL and in those for whom transfusion was withheld until Hb fell below 7.0g/dL.

**METHODS**

**Patients**

This multi-center, prospective, randomized study was conducted in three Brazilian general ICU with a total of 55 beds. Patients who were admitted to one of the participant ICUs with a diagnosis of septic shock\textsuperscript{(22)} between March 1\textsuperscript{st} and August 31\textsuperscript{st} 2008 were included on a non-consecutive basis if they fulfilled the following inclusion criteria: age over 18 years old, a shock diagnosis that was made less than 48 hours prior to participation in the study, Hb levels less than 9.0g/dL and a central venous catheter in the superior vena cava. The exclusion criteria were as follows: pregnancy, known coronary disease, active bleeding and previous participation in the study. The Ethical Committee of the coordinating center approved the study under number 1,177/04, and the trial was registered at ClinicalTrials.gov (NCT01611753). All patients or their legal representatives signed informed consents.

**Red blood cell transfusion characteristics**

Packed RBCs were obtained from the blood bank at each participating site. None of the RBC units transfused in this study was leukoreduced. Storage solution (citrate phosphate dextrose adenine - CPDA-1) was routinely added to the RBCs before storage. The storage period can be extended up to 35 days, and there is no blood bank policy for preferentially transfusing fresh RBCs in ICU patients.

**Study protocol**

We registered only transfusions received while the patients were in shock using vasopressors. We randomized all patients into two groups: patients in Group 1 received transfusions immediately so that their Hb levels were maintained above 9.0g/dL; in Group 2, transfusion was withheld until the patients’ Hb levels fell below 7.0g/dL. We used sealed envelopes with blocks of 10 in each of the participating hospitals for randomization. For practical reasons, the attending physicians and protocol staff were not blinded to the group assignments. Demographic data and the Acute Physiology And Chronic Health Evaluation
II (APACHE II)\textsuperscript{(23)} and Sequential Organ Failure Assessment (SOFA)\textsuperscript{(24)} severity scores were determined on the day of inclusion.

Each time a patient received a transfusion, we collected a set of laboratory tests, including Hb levels, ScvO\textsubscript{2} and lactate at two time points, once immediately before transfusion and once one hour after the end of transfusion. Laboratory tests were collected through a central venous access after discarding 5mL of blood. The correct position of the central venous catheter was assessed using chest radiography. Blood gas data and lactate levels were both measured using a microtechnique in a blood gas analyzer (ABL 700 Radiometer, Copenhagen, Denmark). Hb levels were measured by spectrophotometry (Cell-din\textsuperscript{®} 3700/Abbott\textsuperscript{®}, Illinois, USA).

Immediately prior to each transfusion, we verified that patients had an adequate volemic state, which was defined by a central venous pressure (CVP) above 12mmHg and the decision of the assistant physician that patients did not require another fluid challenge. If the CVP was less than this value, patients received lactated Ringer’s solution or normal saline. Vasopressors were used to maintain the mean arterial pressure above 70mmHg. Only if clinically required, ventilator parameters, vasopressors or dobutamine infusion could be adjusted during the study period. In such a case, the specific transfusion would not be considered in the final analysis.

We assessed Hb levels daily to evaluate the need for transfusion, and as soon as the results became available, patients received an RBC transfusion if required. For each transfusion, only one unit of RBC was transfused. Every transfusion during the study period was registered. We followed the patients until death or the resolution of shock, which was defined as the withdrawal of vasopressors for at least 24 hours. Thereafter, any transfusion was conducted at the discretion of the attending physician.

**Statistical analysis**

The primary endpoint of the study was the effect of transfusion on lactate and ScvO\textsubscript{2}. The pre-specified subgroups were those patients with signs of hypoperfusion detected using lactate levels at least 1.5 times the normal values and those with ScvO\textsubscript{2} below 70%. In addition, we also analyzed patients without signs of hypoperfusion based on normal lactate and ScvO\textsubscript{2} levels.

The sample size was calculated assuming that ScvO\textsubscript{2} would increase in 80% of transfusions for patients in Group Hb\textsubscript{7}, in whom transfusion was withheld until Hb fell below 7.0g/dL compared to only 45% of those in the group transfused to maintain Hb above 9.0g/dL with an alpha error of 0.05 and a power of 80%. Improvement was defined as an increase of 5% over the pre-transfusion ScvO\textsubscript{2}.\textsuperscript{(18)} According to our calculations, 28 transfusions would be necessary in each group; however, to correct for the potential non-parametric distribution of the primary variables, the number was adjusted to 35 transfusions in each group.

Categorical variables were compared using the Pearson chi-squared test corrected by the Mantel-Haenszel method. The distribution of continuous variables was assessed using the Shapiro-Wilk test, and the homogeneity of variance was assessed using the Bartlett test. Normally distributed variables with homogeneous variance were expressed as the mean ± standard deviation, and non-parametric variables were expressed as the median (interquartile 25% - interquartile 75%). Between groups, Student’s t-test and the Mann-Whitney test were used. For comparison within each group, the Wilcoxon paired test was used because Hb, lactate and ScvO\textsubscript{2} were not normally distributed. We also performed a receiver operating characteristic (ROC) curve analysis to assess the accuracy of pre-transfusion Hb levels, pre-transfusion lactate and pre-transfusion ScvO\textsubscript{2} in predicting patients whose ScvO\textsubscript{2} would increase more than 5% with transfusion. We did not consider patients with levels above 75% in this analysis, as the physiological interpretation of this situation is controversial.

In all tests, the results were considered significant if the p value was less than 0.05. Statistical analyses were conducted using Statistical Package for Social Science (SPSS) 17.0 and GraphPad Prism 5.0.

**RESULTS**

Sixty-three patients were included in this study. Overall, there were 74 RBC transfusions with 39 in Group Hb\textsubscript{9} and 35 in Group Hb\textsubscript{7} (Figure 1); 19 patients received more than one transfusion. There were no significant differences between groups regarding demographic variables, severity scores (Table 1) or hemodynamic characteristics immediately before transfusion (Table 2). There were no changes in respiratory parameters or vasoactive drug infusions, and no patient received additional fluids during the transfusion period.
Transfusion increased global Hb levels (p < 0.0001) and, as expected, the pre-transfusion Hb levels were higher in the Group Hb9 (p < 0.0001, Table 3), and pre-transfusion lactate levels were higher in Group Hb7. A significant reduction in lactate levels after transfusion could be found only in Group Hb7 (Group Hb9: p = 0.23, Group Hb7: p = 0.005). Additionally, as expected, ScvO2 was significantly lower at baseline in Group Hb7, and an increase could be detected only in this group (Group Hb9: p = 0.96 and Group Hb7: p < 0.0001). The ROC curves showed that pre-transfusion SvcO2 levels were better than the pre-transfusion Hb or lactate levels (AUC: 0.733 ± 0.064; 95%CI: 0.607 - 0.858) in predicting which patients would respond to transfusion with an increase in ScvO2 greater than 5% (Figure 2).

In 34 transfusions, high lactate levels were present at baseline in 14 cases (35.9%) in Group Hb9 and 20 cases (57.1%) in Group Hb7 (p = 0.06 for difference between groups). In both groups, transfusion was associated with a significant reduction in lactate levels (p = 0.02

Table 1 - Baseline characteristics of the patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Global N = 46</th>
<th>Liberal N = 24</th>
<th>Restrictive N = 22</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male gender</td>
<td>25 (54.3)</td>
<td>14 (68.3)</td>
<td>11 (50.0)</td>
<td>0.76</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.5 ± 1.3</td>
<td>57.4 ± 1.3</td>
<td>57.6 ± 1.4</td>
<td>0.95</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>24 (52.2)</td>
<td>12 (50.0)</td>
<td>12 (54.5)</td>
<td>0.77</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>17 (37.0)</td>
<td>10 (41.7)</td>
<td>7 (31.8)</td>
<td>0.55</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>14 (30.4)</td>
<td>5 (20.8)</td>
<td>9 (40.9)</td>
<td>0.20</td>
</tr>
<tr>
<td>Diabetes</td>
<td>15 (32.6)</td>
<td>9 (37.5)</td>
<td>6 (27.3)</td>
<td>0.53</td>
</tr>
<tr>
<td>Chronic renal disease</td>
<td>22 (47.8)</td>
<td>13 (54.2)</td>
<td>9 (40.9)</td>
<td>0.39</td>
</tr>
<tr>
<td>Chronic pulmonary disease</td>
<td>15 (32.6)</td>
<td>8 (33.3)</td>
<td>7 (31.8)</td>
<td>1.00</td>
</tr>
<tr>
<td>Chronic hepatic disease</td>
<td>8 (17.4)</td>
<td>4 (16.7)</td>
<td>4 (18.2)</td>
<td>1.00</td>
</tr>
<tr>
<td>Immunosuppression</td>
<td>5 (10.9)</td>
<td>2 (8.3)</td>
<td>3 (13.6)</td>
<td>0.65</td>
</tr>
<tr>
<td>Neoplasm</td>
<td>10 (21.7)</td>
<td>6 (25.0)</td>
<td>4 (18.2)</td>
<td>0.72</td>
</tr>
<tr>
<td>Cerebral vascular disease</td>
<td>6 (13.0)</td>
<td>2 (8.3)</td>
<td>4 (18.2)</td>
<td>0.40</td>
</tr>
<tr>
<td>Source of infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary</td>
<td>17 (37.0)</td>
<td>9 (37.5)</td>
<td>8 (36.4)</td>
<td>0.80</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>16 (34.8)</td>
<td>7 (29.2)</td>
<td>9 (40.9)</td>
<td>0.61</td>
</tr>
<tr>
<td>Abdominal</td>
<td>9 (19.6)</td>
<td>5 (20.8)</td>
<td>4 (18.2)</td>
<td>0.73</td>
</tr>
<tr>
<td>Other</td>
<td>4 (8.7)</td>
<td>3 (12.5)</td>
<td>1 (4.5)</td>
<td>0.31</td>
</tr>
<tr>
<td>APACHE II</td>
<td>14.0 ± 3.6</td>
<td>13.9 ± 3.7</td>
<td>14.2 ± 3.6</td>
<td>0.77</td>
</tr>
<tr>
<td>SOFA</td>
<td>6.8 ± 0.9</td>
<td>6.7 ± 0.7</td>
<td>6.9 ± 1.1</td>
<td>0.46</td>
</tr>
<tr>
<td>Admission Hb (g/dL)</td>
<td>(9.1 - 11.0)</td>
<td>(9.5 - 12.0)</td>
<td>(8.8 - 9.8)</td>
<td>0.15</td>
</tr>
<tr>
<td>Mortality</td>
<td>24 (52.1)</td>
<td>13 (54)</td>
<td>11 (50)</td>
<td>0.87</td>
</tr>
</tbody>
</table>

Table 2 - Hemodynamic profile immediately prior to transfusion

<table>
<thead>
<tr>
<th>Variable</th>
<th>Global N = 74</th>
<th>Liberal N = 39</th>
<th>Restrictive N = 35</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVP (mmHg)</td>
<td>17.4 ± 2.6</td>
<td>17.0 ± 2.4</td>
<td>17.9 ± 2.9</td>
<td>0.15</td>
</tr>
<tr>
<td>Dobutamine use</td>
<td>55 (74.3)</td>
<td>29 (52.7)</td>
<td>26 (47.3)</td>
<td>1.00</td>
</tr>
<tr>
<td>Dobutamine dose (µg/kg/min)</td>
<td>5.6 ± 2.1</td>
<td>5.1 ± 2.2</td>
<td>5.8 ± 2.0</td>
<td>0.20</td>
</tr>
<tr>
<td>Norepinephrine dose (µg/kg/min)</td>
<td>0.3 ± 0.1</td>
<td>0.3 ± 0.1</td>
<td>0.3 ± 0.1</td>
<td>0.98</td>
</tr>
</tbody>
</table>

CVP - central venous pressure. The results are expressed as numbers (%) or mean ± standard deviation. Chi square test, t student or Mann-Whitney test.
In the transfusions for which the pre-transfusion lactate levels were normal (n = 40), a decrease was detected on only six occasions (4 in Group Hb9 and 2 in Group Hb7 (p = 0.81). In 33 transfusions, baseline ScvO₂ was between 70% and 75%. Although all four cases in which ScvO₂ decreased after transfusion were from Group Hb9, this difference in distribution was not significant (p = 0.17; Table S4 in the electronic supplementary material).

DISCUSSION

In this physiological prospective randomized study of septic shock patients, we demonstrate that RBC transfusion leads to an increase in lactate and ScvO₂ levels in patients with altered baseline levels, even if their Hb levels were between 7.0 and 9.0g/dL. No signs of worsened perfusion, as assessed by these variables, could be found, even in patients with normal and higher levels of Hb. Moreover, we found that pre-transfusion ScvO₂ was a better predictor of an increase in ScvO₂ with transfusion than pre-transfusional Hb or lactate levels.

Hemoglobin level is one of the determinants of oxygen delivery. As expected, patients randomized to the Group Hb7, who consequently had lower levels of Hb, had a higher frequency of lower levels of ScvO₂ and higher lactate levels. However, the threshold at which oxygen supply is impaired due to Hb in critically ill patients is not known. Maintaining Hb levels at 7.0g/dL has been considered safe, primarily as a result of a previous randomized study conducted in a general population of critically ill but stable patients. (25) However, there has been no randomized study comparing transfusion triggers in cases of impaired oxygen delivery/oxygen consumption ratio status, as found in septic patients. The recent published study of Holst et al., in which septic shock patients were randomized to a restrictive group (transfusion only if Hb < 7.0g/dL) or a liberal group (transfusion if Hb < 9.0g/dL) did not show differences between the groups, favoring the restrictive approach. (21) However, the study design did not focus on the presence of hypoperfusion because patients were transfused when Hb fell below each group trigger during their entire ICU stay regardless the presence of shock or signs of hypoperfusion.

Although this study is small with only physiological endpoints, its results suggests that the presence of
hyperlactatemia or low ScvO₂ should be considered in future clinical studies that address this problem. It might be possible that a liberal approach is superior to a restrictive one when considering only patients who actually need to improve their oxygen delivery. Thus, if only patients with Hb levels ≤ 9.0g/dL were included and the presence of signs of hypoperfusion were required to indicate transfusion, we would be able to properly compare two strategies of transfusion: an early transfusion strategy initiated when Hb levels drop below 9.0g/dL; and a late transfusion strategy, when transfusions are indicated only when Hb drops below 7.0g/dL.

A first step to such a randomized interventional study aimed at establishing the best Hb levels in septic patients would be to determine if transfusion is able to lower lactate and increase ScvO₂ levels, even in patients with intermediate Hb levels, as shown in this study. The effect of Hb on hemodynamic variables has been previously demonstrated by Adamczyk et al. in postoperative patients for whom an improvement in ScvO₂ could be found only in patients with lower ScvO₂ levels when their Hb levels were between 7.0g/dL and 9.0g/dL. However, these authors did not analyze patients with the lower Hb levels currently used as an indication for transfusion (i.e., below 7.0g/dL), which precludes any attempt to relate responses to Hb levels. This improvement in tissue oxygenation may have been related to an improvement in oxygen content; however, a possible mechanism would have been the improvement of cardiac output secondary to an increase in preload. This cannot be ruled out because this variable was not assessed in these patients. The absence of this measurement is one of this study’s limitations because it might compromise the quality of the hemodynamic assessments presented. Although all patients were stabilized before inclusion, and CVP levels were above 12mmHg, we did not measure fluid responsiveness; thus, we cannot be certain that transfusion would not have led to an increase in cardiac output.

However, this study has numerous strengths. First, the studied population is homogeneous, only including septic shock patients. The majority of previous studies included a heterogeneous population of critically ill individuals, such as surgical patients without hemodynamic instability, shock patients with multiple etiologies or septic patients without shock. Studies evaluating only septic shock patients were not randomized and included only a small number of transfusions (e.g., 15 to 35 transfusions); as a result, they lacked statistical power to demonstrate slight differences in these variables. Second, the number of transfusions in this study allowed us to analyze subgroups of patients with and without tissue oxygenation abnormalities. This type of analysis was not emphasized in many previous studies. Third, the patients used in this study were randomized into two different transfusion threshold levels. This strategy allows a comparison between groups without any difference in disease severity, and a clear separation regarding pre-transfusion Hb levels could be established.

Some limitations are also noteworthy. First, the evaluation of a transfusion’s beneficial and deleterious effects based only on ScvO₂ and lactate is limited. The use of these variables to assess perfusion is also a limitation. We did not assess any clinical outcomes. Second, patients were selected on a non-consecutive basis, and more than one episode of transfusion per patient was registered, which could have resulted in a selection bias. However, the transfusions were not given at the same time point, and only one red blood cell unit was given at each time. This resulted in different hemodynamic conditions and baseline Hb levels for each transfusion. We recalculated data using only the first transfusion for each patient, and the results were similar. Third, we might interpret the unknown storage duration as a limitation because it precludes an eventual association of this variable with the transfusion outcome. However, there are contradictory data regarding the relevance of storage time to clinical, microcirculatory and physiological variables after transfusion. Although we did not measure the storage period of the RBCs transfused in this study, a previous report demonstrated that the median storage time of RBCs in blood banks was 14 (7-21) days, suggesting that at least half of this study’s patients received fresh blood. Fourth, as already mentioned, the absence of cardiac output measurements and hemodynamic data after transfusion prevents analysis of the correlation between tissue oxygenation improvement and a possible increase in cardiac output secondary to increased preload after transfusion. Fifth, although we collected post-transfusion blood samples
immediately after transfusion and there was no change in ventilator parameters or arterial oxygenation, we cannot eliminate the possibility that the observed changes in ScvO$_2$ and lactate could be influenced by modifications in oxygen saturation, changes in oxygen consumption ratio or as a consequence of aerobic glycolysis. Finally, we did not directly measure tissue perfusion.

**CONCLUSION**

In conclusion, red blood cell transfusion in septic shock patients with low central venous oxygen saturation or high lactate levels can result in an increase in central venous oxygen saturation and a decrease in lactate levels in patients with hemoglobin levels below 7.0g/dL and in patients with hemoglobin levels between 7.0 and 9.0g/dL. In patients with normal lactate and central venous oxygen saturation levels, transfusion did not change these variables, even in individuals with higher hemoglobin levels.

**Authors’ contributions**

B. F. Mazza and F. R. Machado designed and coordinated this study; B. F. Mazza, F. G. R. Freitas, M. M. O. Barros, L. C. P. Azevedo and F. R. Machado contributed to data collection; B. F. Mazza and F. R. Machado drafted the manuscript; and B. F. Mazza, L. C. P. Azevedo, F. G. R. Freitas and F. R. Machado revised the article. All authors have read and approved the final manuscript.

**ACKNOWLEDGMENTS**

We are grateful to the healthcare professionals from the participating intensive care units in the following institutions: Anesthesiology, Pain and Critical Care Discipline - Universidade Federal de São Paulo, São Paulo, Brazil; Santa Casa de Misericordia, Cruzeiro (SP), Brazil and Hospital Antoninho da Rocha Marmo, São José dos Campos - SP, Brazil.

**RESUMO**

**Objetivo:** Avaliar os efeitos imediatos da transfusão de hemácias nos níveis de saturação venosa central de oxigênio e de lactato em pacientes com choque séptico usando diferentes níveis gatilho de hemoglobina para indicar transfusão.

**Métodos:** Incluímos pacientes com diagnóstico de choque séptico nas últimas 48 horas e níveis de hemoglobina abaixo de 9,0g/dL. Os pacientes foram randomizados para receber imediatamente transfusão se as concentrações se mantivessem acima de 9,0g/dL (Grupo Hb9) ou adiar a transfusão até que a hemoglobina caísse abaixo de 7,0g/dL (Grupo Hb7). Os níveis de hemoglobina, lactato e saturação venosa central de oxigênio foram determinados antes e 1 hora após cada transfusão.

**Resultados:** Incluímos 46 pacientes, totalizando 74 transfusões. Os pacientes do Grupo Hb7 tiveram uma redução significante nos níveis medianos de lactato de 2,44 (2,00 - 3,22) mMol/L para 2,21 (1,80 - 2,79) mMol/L; p = 0,005. Isto não foi observado no Grupo Hb9 [1,90 (1,80 - 2,65) mMol/L para 2,00 (1,70 - 2,41) mMol/L; p = 0,23]. A saturação venosa central de oxigênio aumentou no Grupo Hb7 [68,0 (64,0 - 72,0)% para 72,0 (69,0 - 75,0)%; p < 0,0001], mas não no Grupo Hb9 [72,0 (69,0 - 74,0)% para 72,0 (71,0 - 73,0)%; p = 0,98]. Pacientes com elevados níveis de lactato ou saturação venosa central de oxigênio menor que 70% na avaliação basal tiveram um aumento significante nessas variáveis, independentemente dos níveis basais de hemoglobina. Pacientes com valores normais não demonstraram diminuição em quaisquer dos grupos.

**Conclusão:** A transfusão de hemácias aumentou a saturação venosa central de oxigênio e diminuiu os níveis de lactato em pacientes com hipoperfusão, independentemente de seus níveis basais de hemoglobina. A transfusão não pareceu influenciar essas variáveis em pacientes sem hipoperfusão.

ClinicalTrials.gov NCT01611753

**Descritores:** Transfusão de eritrócitos; Isquemia; Choque séptico; Sepse; Oxigenação
REFERENCES


